Skip to main content
SpringerLink
Log in
Book cover

Myelodysplastic Syndromes pp 119–129Cite as

Lenalidomide for the Treatment of MDS

  • Chapter
  • First Online:

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic disorders characterized by bone marrow (BM) failure, dysplasia, and an increased risk of developing acute myeloid leukemia (AML) [1]. The most prevalent cytogenetic abnormality is a partial deletion of the long arm of chromosome 5, del(5q), which is present in about 15% of cases [2]. Anemia is the predominant cytopenia in the large majority of low-risk MDS cases, being the focus of most therapeutic interventions. It often requires repeated RBC transfusions, leading to potential iron overload.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83:71–86.

    PubMed  CAS  Google Scholar 

  2. Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011;29:1963–70.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011;29:303–9.

    Article  CAS  PubMed  Google Scholar 

  4. Sloand EM, Olnes MJ, Shenoy A, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol. 2010;28:5166–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549–57.

    Article  CAS  PubMed  Google Scholar 

  6. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–65.

    Article  CAS  PubMed  Google Scholar 

  7. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76.

    Article  CAS  PubMed  Google Scholar 

  8. Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007;104:11406–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. List A, Baker A, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control. 2006;13:4–11.

    Article  PubMed  Google Scholar 

  10. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010;363:1025–37.

    Article  CAS  PubMed  Google Scholar 

  11. Gohring G, Giagounidis A, Busche G, et al. Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide. Haematologica. 2011;96:319–22.

    Article  PubMed  Google Scholar 

  12. Wei S, Chen X, McGraw K, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013;32:1110–20.

    Article  CAS  PubMed  Google Scholar 

  13. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009;106:12974–9.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345–50.

    Article  CAS  PubMed  Google Scholar 

  15. Kronke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523:183–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002;99:4638–41.

    Article  CAS  PubMed  Google Scholar 

  17. Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126:2366–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jadersten M, Saft L, Pellagatti A, et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica. 2009;94:1762–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29:1971–9.

    Article  PubMed  Google Scholar 

  20. Schuler E, Giagounidis A, Haase D, et al. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia. 2016;30:1580–2.

    Article  CAS  PubMed  Google Scholar 

  21. Jadersten M, Karsan A. Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring. Haematologica. 2011;96:177–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Narla A, Dutt S, McAuley JR, et al. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood. 2011;118:2296–304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ximeri M, Galanopoulos A, Klaus M, et al. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 2010;95:406–14.

    Article  CAS  PubMed  Google Scholar 

  24. Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26:5943–9.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev Hematol. 2011;4:61–9.

    Article  CAS  PubMed  Google Scholar 

  26. Gohring G, Giagounidis A, Busche G, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2010;89:365–74.

    Article  CAS  PubMed  Google Scholar 

  27. Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia. 2012;26:1286–92.

    Article  CAS  PubMed  Google Scholar 

  28. Ades L, Le Bras F, Sebert M, et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica. 2012;97:213–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kuendgen A, Lauseker M, List AF, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 2013;27:1072–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. List AF, Bennett JM, Sekeres MA, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2015;29:2452.

    Article  CAS  PubMed  Google Scholar 

  31. Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 2009;113:3947–52.

    Article  CAS  PubMed  Google Scholar 

  32. Ades L, Prebet T, Stamatoullas A, et al. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myelodysplasies. Haematologica. 2017;102:728–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012;120:4945–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86–93.

    Article  CAS  PubMed  Google Scholar 

  35. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008;5:e35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34:2988–96.

    Article  CAS  PubMed  Google Scholar 

  37. Toma A, Kosmider O, Chevret S, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016;30:897–905.

    Article  CAS  PubMed  Google Scholar 

  38. List AF, Sun Z, Verma A, et al. Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS): results of the E2905 intergroup study-an ECOG-ACRIN cancer research group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health. Blood. 2016;128:223.

    Google Scholar 

Download references

Acknowledgment

This work was in part supported by the Deutsche José Carreras Leukämie-Stiftung.

Author information

Authors and Affiliations

  1. Marien Hospital Düsseldorf, Klinik für Onkologie, Hämatologie und Palliativmedizin, Düsseldorf, Germany

    Aristoteles Giagounidis

  2. Hopital Saint Louis and Paris 7 University, Paris, France

    Lionel Adès

Authors
  1. Aristoteles Giagounidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lionel Adès
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Aristoteles Giagounidis or Lionel Adès .

Editor information

Editors and Affiliations

  1. Medizinische Klinik und Poliklinik 1, Universitätsklinikum Dresden Medizinische Klinik und Poliklinik 1, Dresden, Sachsen, Germany

    Uwe Platzbecker

  2. Department of Hematology, Hospital Saint Louis, Paris, France

    Pierre Fenaux

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Giagounidis, A., Adès, L. (2018). Lenalidomide for the Treatment of MDS. In: Platzbecker, U., Fenaux, P. (eds) Myelodysplastic Syndromes . Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-76879-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-76879-3_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-76878-6

  • Online ISBN: 978-3-319-76879-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation